# A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

> **NCT06561386** · PHASE3 · RECRUITING · sponsor: **Bristol-Myers Squibb** · enrollment: 1000 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Relatlimab
- **DRUG:** Pembrolizumab
- **DRUG:** Carboplatin
- **DRUG:** Pemetrexed
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT06561386
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-07
- **Primary completion:** 2030-07-30
- **Final completion:** 2032-08-04
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06561386

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06561386, "A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06561386. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*